Scalar Gauge Management LLC Sells 428,513 Shares of Enfusion, Inc. (NYSE:ENFN)

Scalar Gauge Management LLC decreased its position in Enfusion, Inc. (NYSE:ENFN - Free Report) by 94.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 25,000 shares of the company's stock after selling 428,513 shares during the quarter. Enfusion comprises approximately 0.1% of Scalar Gauge Management LLC's investment portfolio, making the stock its 27th biggest position. Scalar Gauge Management LLC's holdings in Enfusion were worth $258,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. KLP Kapitalforvaltning AS bought a new position in shares of Enfusion during the fourth quarter worth approximately $75,000. Quantbot Technologies LP bought a new position in Enfusion during the 4th quarter worth $144,000. Paloma Partners Management Co bought a new position in Enfusion during the 3rd quarter worth $157,000. Intech Investment Management LLC acquired a new position in Enfusion in the 4th quarter valued at $191,000. Finally, Centiva Capital LP lifted its position in shares of Enfusion by 5.0% during the 3rd quarter. Centiva Capital LP now owns 25,596 shares of the company's stock valued at $243,000 after acquiring an additional 1,227 shares during the period. Institutional investors own 81.05% of the company's stock.

Enfusion Price Performance

Shares of ENFN stock traded down $0.42 on Friday, hitting $10.58. 890,737 shares of the company's stock were exchanged, compared to its average volume of 563,652. The stock has a market cap of $1.36 billion, a P/E ratio of 264.19, a price-to-earnings-growth ratio of 1.85 and a beta of 0.95. Enfusion, Inc. has a 12 month low of $7.83 and a 12 month high of $11.80. The company has a 50 day moving average of $11.18 and a 200 day moving average of $10.27.

Enfusion (NYSE:ENFN - Get Free Report) last issued its earnings results on Monday, March 3rd. The company reported $0.01 earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.02). The company had revenue of $52.94 million during the quarter, compared to analyst estimates of $53.98 million. Enfusion had a net margin of 1.70% and a return on equity of 6.67%. Sell-side analysts predict that Enfusion, Inc. will post 0.06 EPS for the current fiscal year.

Insider Buying and Selling at Enfusion

In related news, COO Neal Pawar sold 2,769 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $11.48, for a total value of $31,788.12. Following the completion of the sale, the chief operating officer now directly owns 1,231,627 shares in the company, valued at $14,139,077.96. This represents a 0.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Bradley Herring sold 4,134 shares of Enfusion stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total value of $41,877.42. Following the transaction, the chief financial officer now directly owns 266,369 shares in the company, valued at $2,698,317.97. The trade was a 1.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 77,346 shares of company stock worth $868,109. 36.44% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

ENFN has been the topic of a number of recent analyst reports. Piper Sandler raised their price target on Enfusion from $10.00 to $11.50 and gave the stock a "neutral" rating in a research report on Monday, December 23rd. William Blair restated a "market perform" rating on shares of Enfusion in a research report on Monday, January 13th. Finally, Stifel Nicolaus increased their price target on shares of Enfusion from $11.00 to $13.00 and gave the stock a "buy" rating in a research report on Wednesday, December 18th.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.